Hepion Pharmaceuticals Inc. (CTRV)’s Financial Results Comparing With Rexahn Pharmaceuticals Inc. (NASDAQ:REXN)

As Biotechnology businesses, Hepion Pharmaceuticals Inc. (NASDAQ:CTRV) and Rexahn Pharmaceuticals Inc. (NASDAQ:REXN), are affected by contrast. This especially applies to their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hepion Pharmaceuticals Inc. 11 0.00 N/A -81.90 0.00
Rexahn Pharmaceuticals Inc. 5 0.00 N/A -5.12 0.00

Demonstrates Hepion Pharmaceuticals Inc. and Rexahn Pharmaceuticals Inc. earnings per share, gross revenue and valuation.


Table 2 has Hepion Pharmaceuticals Inc. and Rexahn Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Hepion Pharmaceuticals Inc. 0.00% 0% 0%
Rexahn Pharmaceuticals Inc. 0.00% -132% -86.6%

Analyst Recommendations

In next table is delivered Hepion Pharmaceuticals Inc. and Rexahn Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Hepion Pharmaceuticals Inc. 0 0 0 0.00
Rexahn Pharmaceuticals Inc. 0 1 0 2.00

Competitively the consensus target price of Rexahn Pharmaceuticals Inc. is $3, which is potential 35.14% upside.

Institutional & Insider Ownership

Institutional investors held 3.72% of Hepion Pharmaceuticals Inc. shares and 12.4% of Rexahn Pharmaceuticals Inc. shares. Hepion Pharmaceuticals Inc.’s share held by insiders are 36.42%. Insiders Competitively, held 0.2% of Rexahn Pharmaceuticals Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Hepion Pharmaceuticals Inc. -7.01% -16.55% -75.65% -84.73% -94.67% -81.86%
Rexahn Pharmaceuticals Inc. -0.39% -3.67% -17.95% -32.26% -69.2% -54.12%

For the past year Rexahn Pharmaceuticals Inc. has weaker performance than Hepion Pharmaceuticals Inc.


On 4 of the 7 factors Rexahn Pharmaceuticals Inc. beats Hepion Pharmaceuticals Inc.

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.